Needham Maintains Buy on Cellebrite DI, Raises Price Target to $24
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $22 to $24.
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and raises the price target from $22 to $24.